XORTX Therapeutics Inc.
XRTXNASDAQHealthcare● Active
$2.18
$-0.03(-1.36%)
Market Cap$607106
P/E Ratio—
52W High$7.05
52W Low$1.725
XORTX Therapeutics Inc. (XRTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
XRTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.58
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
🔥 7-Quarter EPS Beat Streak
XRTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 15, 2026 | — | -$0.58 | — | — | — | — |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.84 | -$0.45 | +46.1% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.17 | -$0.13 | +22.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.25 | -$0.19 | +24.0% | — | — | — |
| ▲ Q2 FY2025 | May 19, 2025 | -$0.27 | -$0.19 | +29.6% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.29 | -$0.19 | +34.5% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.38 | -$0.20 | +47.8% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026
EPS Actual
-$0.58
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.45
EPS Est.
-$0.84
EPS Surpr.
+46.1%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.17
EPS Surpr.
+22.2%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.25
EPS Surpr.
+24.0%
Revenue
—
Q2 FY2025
May 19, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.27
EPS Surpr.
+29.6%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.29
EPS Surpr.
+34.5%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.20
EPS Est.
-$0.38
EPS Surpr.
+47.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.84 | $-0.84 | $-0.84 | 1 |
| Q3 FY2025 | $-0.17 | $-0.17 | $-0.17 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 15, 2026 | — | $2.01 | $2.59 | +28.86% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +46.1% | $2.00 | $2.02 | +1.00% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +22.2% | $2.80 | $2.78 | -0.71% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +24.0% | $4.40 | $4.45 | +1.14% |
| ▲ Q2 FY2025 | May 19, 2025 | +29.6% | $5.35 | $4.60 | -14.02% |
| ▲ Q2 FY2025 | May 15, 2025 | +34.5% | $4.94 | $4.70 | -4.86% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +47.8% | $6.50 | $7.00 | +7.69% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +112.0% | $7.15 | $7.32 | +2.38% |
Q2 FY2026+28.86%
Report Date
May 15, 2026
EPS Beat/Miss
—
Price Before
$2.01
Price After
$2.59
Q1 FY2026+1.00%
Report Date
Feb 26, 2026
EPS Beat/Miss
+46.1%
Price Before
$2.00
Price After
$2.02
Q4 FY2025-0.71%
Report Date
Nov 14, 2025
EPS Beat/Miss
+22.2%
Price Before
$2.80
Price After
$2.78
Q3 FY2025+1.14%
Report Date
Aug 14, 2025
EPS Beat/Miss
+24.0%
Price Before
$4.40
Price After
$4.45
Q2 FY2025-14.02%
Report Date
May 19, 2025
EPS Beat/Miss
+29.6%
Price Before
$5.35
Price After
$4.60
Q2 FY2025-4.86%
Report Date
May 15, 2025
EPS Beat/Miss
+34.5%
Price Before
$4.94
Price After
$4.70
Q4 FY2024+7.69%
Report Date
Nov 14, 2024
EPS Beat/Miss
+47.8%
Price Before
$6.50
Price After
$7.00
Q3 FY2024+2.38%
Report Date
Aug 14, 2024
EPS Beat/Miss
+112.0%
Price Before
$7.15
Price After
$7.32
Avg Beat Reaction-1.05%
Beat Rate7 / 8 quarters
Largest Move+28.86% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: XRTX ends December
XORTX Therapeutics Inc. (XRTX) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.58 (in line with the analyst consensus of —). XRTX has beaten EPS estimates for 7 consecutive quarters. The next XRTX earnings date is expected around September 1, 2026.
Each quarter, investors track XRTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. XRTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
XRTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
XRTX earnings · 4 questionsXORTX Therapeutics Inc.'s next earnings report is expected around September 1, 2026. XRTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; XRTX historically reports after market close (AMC).
XRTX earnings datewhen is XRTX earningsXRTX next earnings datewhen does XRTX report earningsXRTX earnings calendar
▸ Source: FMP · XORTX Therapeutics Inc. SEC filings · US GAAP · XORTX Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026